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Abstract 
     Urolithiasis is the presence of urinary calculi (urinary stones) at any level along the 
excretory system. Establishing accurate and complete mineral composition of the stones is 
one of the main factors in deciding the best steps for therapy and recurrence prevention. 
     Currently, infrared spectroscopy (IRS) and x-ray diffractometry (XRD) provide bulk 
composition results of urinary calculi in powdered form. Clinicians use the results to 
prescribe medical and dietary measures to restore the physiologic chemical balance of urine 
or rather alter it for the purpose of decreasing the crystallization rate of single or multiple 
minerals. As current methods have been shown reliable from a clinical perspective, they may 
also be, due to sampling bias, prone to missing the core components from the analysis. 
     This work shows that coherent scatter computed tomography (CSCT) is a composition-
imaging, laboratory method able to provide both composition analysis of intact calculi and a 
distribution map of minerals within the stone, including its core and the surrounding layers. 
Aspects related to CSCT’s measurement uncertainties, CSCT’s analysis of kidney stones in 
both intact and pulverized forms and the summarized conclusions of a comparison study 
between CSCT and IRS are presented. With this new knowledge clinicians may choose to 
employ a core-targeted prevention plan in the management of urolithiasis to further decrease 
the recurrence rate in these patients.  
Keywords 
Coherent scatter, urolithiasis, core composition imaging, recurrence prevention. 
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Chapter 1  
1 Introduction 
Urolithiasis is a serious health problem in humans and animals. Diagnosis can be 
straughtforward based on clinical symptoms, but in imaging techniques are often used for 
confirmation [1]. Procedures with various degrees of invasiveness are used for kidney 
stone removal. Despite advanced knowledge of both mineral and organic chemical 
constituents found in stone composition, and well established preventive measures for 
each constituent, prevalence and recurrence rates of urolithiasis are still on the rise [2]. 
Kidney stone recurrence ratesare very high, and part of a comprehensive program for 
medical management of the patients is to attempt to prevent future recurrences.  
Composition analysis after removal is one of the main considerations required for 
effective recurrence prevention [2].  Current analysis techniques, including infrared 
spectroscopy (IRS) and x-ray diffractometry (XRD) require pulverization of the stone 
before analysis, and since stones often consist of layers of different components, these 
methods are not able to specifically determine the composition at the core of the stone 
associated with the initial crystallization event. A method of analysis that provides 
structural information as well as composition may allow for identification of the core 
material and solve this problem.  This thesis describes the results of a study that uses a 
novel analysis tool developed in our laboratory that generates two or three-dimensional 
images showing the distribution of component materials in an intact stone.  These 
material “maps” show how the stone components are often structured into layers, and that 
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the core material, often a small fraction of the total stone mass, can be miss-identified by 
conventional methods. 
This chapter describes urolithiasis with respect to its history, clinical symptoms, 
epidemiology, treatment and prevention. It also summarizes current composition-analysis 
techniques used in laboratories, as well as our new method, coherent-scatter computed 
tomography (CSCT), an image-based technique for analysis of urinary calculi in intact 
form. 
 
1.1 Overview of urolithiasis 
Kidney stone disease has been known to affect humans and animals for hundreds of years 
[3]. With people recognizing with ease the signs and symptoms of urolithiasis, came the 
struggle to find more efficient ways to treat and, even better, to prevent the occurrence 
and relapses of kidney stones.  
While in 1500 BC the Ebes Papirus mentioned the “bread in a rotten condition” to treat 
bladder diseases and 1000 years later Hippocrates recognized the danger of bladder 
stones and initiated the analysis of urine by inspection and tasting [3], it was only in the 
past few centuries that more modern, thorough approaches to urolithiasis LEAD to the 
discovery of more beneficial diagnosis and therapy modalities of urinary calculi. 
Although many urological treatments and techniques were developed as early ast the 16th 
century, it is remarkable that the first x ray of a kidney stone (in an abdominal film) was 
reported in 1896, the same year as the first reporting of the discovery of x rays by 
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Roentgen. Imaging kidney stones by x-rays has quickly developed as one of x-ray 
imaging applications [4].  The first retroperitoneal pneumatography in 1921, and the first 
intravenous urography in 1929 [3], were two other important milestones in the use of x 
rays for imaging kidney stones and their intimate anatomical structures. 
The high social impact and economic burden of urolithiasis continues to drive the 
development of new solutions for treatment and prevention today. 
 
1.2 Urolithiasis-epidemiology and clinical features 
It has been determined that all categories of population are at various degrees of risk of 
developing urinary calculi [5]. Uncommon before the age of 20, kidney stone disease 
observes an increased rate of incidence with age and remains elevated until the age of 70, 
when rates tend to decrease [6]. There is a documented higher risk of developing kidney 
stones in men that in woman [6] [7] [5] [8]. Also, race, diet and lifestyle habits have an 
important influence on urolithiasis occurrence [5] [8]. It has been underlined by several 
studies that whites have the highest while blacks have the lowest prevalence rate for 
kidney stone disease. Hispanics and Asians have intermediate prevalence rates [5]. 
Seasonal variation, climate and geographical influences have been demonstrated by 
higher prevalence rates in populations living in dry and hot areas. In the United States, 
people living in southern states are prone to develop kidney stones more often than those 
living in northern states. This is likely due to inadequate hydration effects, and it has been 
estimated that by the year 2095 areas representing a high risk for developing kidney 
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stones will move further northward due to global warming and will comprise around 70% 
of the United States’ population [9]. 
Various underlying disorders influence kidney stone formation and recurrence.  For 
example, links have been demonstrated between cystinuria and cystine stones, between 
certain urinary tract infections and struvite stones, and between gout and uric acid stones.   
Hyperparathyroidism, hyperthyroidism, renal anatomical anomalies are also associated 
with a high risk of kidney stone formation [6] [7] [5] [8] [9] [10] [2] [11] [12] [13], and 
must also be considered as part of the treatment and recurrence prevention strategies. 
Most stones evolve undetected for long periods, often many years.  In case of non-
obstructive stones, haematuria is usually the first clinical feature that raises suspicion of 
the disease. Stones with diameter under 5 mm can easily start their passage through the 
uretero-pelvic junction and can generate obstructions and consequently renal colic 
(Figure 1). This starts often as a mild discomfort or vague pain and reaches a peak of 
severity in about 30-60 minutes [5] [7]. The pain is not influenced by position or 
movement; it is often associated with nausea and vomiting and cannot be relieved by 
non-narcotic pain killers [5]. When stone obstructs in lower excretory system main 
symptoms are bladder instability, dysuria and urinary frequency [5] [10] [12].                                            
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Figure 1.Excretory system schematic with potentially obstructive stones being 
present in the kidney and ureter. 
These severe and debilitating symptoms emphasize the importance of conducting 
extensive research in order to discover new ways for more effective diagnosis, treatment 
and prevention of urolithiasis and its frequent recurrent episodes. 
 
1.3 Urolithiasis-therapy 
Comprehensive treatment of kidney stone disease must address acute episodes, stone 
removal and recurrence prevention. As in any acute scenario, the first thing to alleviate is 
the pain. A combination of anti-inflammatory and spasmolytic agents is usually 
attempted first. Narcotics may also be considered if the pain does not resolve. The 
intense, colicky pain explains the great social impact of urolithiasis as patients in some 
occupations, like airplane pilots [5] are not permitted to work even if they have 
asymptomatic stones. Notable also is that renal colic is so severe that it often requires the 
prescription of narcotic analgesics. 
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When the pain is under control, patient management continues with a decision for 
strategy of stone removal.  Small stones that are less than approximately 5mm are often 
left in place and, based on location, may be eliminated spontaneously with no further 
intervention. For larger stones, or stones whose evolution is not expected to regress, as 
well as certain types of stones (staghorn or infectious stones), surgery is the elected 
option for removal. Larger stones that occupy part of, or all of, the renal pelvis must be 
removed to avoid potential renal functional complications.  
Extracorporeal shockwave lithotripsy (ESWL) is a minimally invasive, outpatient 
procedure that crushes the stones in situ and the resulted fragments are expected to be 
eliminated afterwards with the urine flow. The procedure is relatively simple (Figure 2), 
but not without complications and has to be repeated when large fragments remain in 
place.  
 
Figure 2. Extracorporeal shockwave litothripsy scematic diagram 
(http://www.healthxchange.com.sg/healthyliving/SexualHealth/Pages/Kidney-
stones.aspx) 
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Endoscopic procedures (ureteroscopy, ureterorenoscopy) are outpatient procedures used 
quite often for stone removal, offering easy access to stones lodged in urethra, ureters or 
the vezico-ureteral junction (figure 3).  
 
Figure 3. Ureteroscopy schematic diagram 
(http://www.healthxchange.com.sg/healthyliving/SexualHealth/Pages/Kidney-
stones.aspx) 
Percutaneous nephrolithotomy (PCNL) is an invasive intervention (figure 4) reserved for 
large calculi in the renal pelvis [5]. Classic, open surgery is being done in extremely rare 
cases.  
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Figure 4. Percutaneous nephrolithotomy schematic diagram 
(http://www.healthxchange.com.sg/healthyliving/SexualHealth/Pages/Kidney-
stones.aspx) 
     
1.4 Urolithiasis-recurrence prevention 
Once the stones are removed or expected to be removed by treating the causative 
element, the most important management step is deciding on a recurrence prevention 
plan. This may be dealt with by prescribing certain medications that address an already 
diagnosed underlying condition, such as in hyperparathyroidism or, more often, by 
recommending medication and diet based on bulk composition analyses.  General 
preventive measures, such as increasing urinary volume [2] [5] [8] [9] [10] [11] [12] [13] 
to dilute the urine are always part of the recurrence prevention plan. This can be 
accomplished by increasing the daily fluid intake to 2.5 – 3.0 litres. Also, in case of 
calcium based stones, a decrease in calcium and oxalate intake and administration of 
potassium citrate and thiazide diuretics was proven to reduce the recurrence rate for 
calcareous stones. Ultimately, curative antibiotic treatment of persistent, chronic urinary 
tract infections with urea splitting bacteria can reduce the recurrence of infectious stones. 
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Diet low in methionine and sodium can decrease the frequency of cystine stones. Purine 
restriction, urinary pH elevation and administration of allopurinol can reduce 
hyperuricosuria [2] [8] [10] [11] [12] [13]. 
 
1.5 Kidney stone composition and metabolic associations 
1.5.1 Common kidney stone minerals 
All kidney stones contain 2-5% matrix (macromolecules and other cellular components) 
and 95-98% crystalline material. Most human stones are multicomponent containing 
more than one crystalline material [3] [14]. The most frequent minerals in kidney stone 
composition are calcium based, accounting for approximately 50-60% of all stones [3] 
[6] [7] [8] [10] [13]. The stones containing calcium salts can be either idiopathic or 
appear to be related to a pre-existing condition. Among non-calcium based stone 
components, the most frequent are struvite, uric acid and cystine.  
Calcium oxalate monohydrate (COM), also called whewellite (CaC2O4·H2O) is rarely 
found in nature but is the most frequent mineral in kidney stone composition. It presents 
as small, smooth, and yellow-green to brown crystals traditionally difficult to fragment 
[3] by shockwave lithotripsy.  
Calcium oxalate dehydrate (COD), also called weddellite (CaC2O4·2H2O), was 
discovered in the 1930s in bottom sediments of the Weddell Sea in Antarctica. It is often 
found as sharp, yellow crystals deposited on the outer surface of a smooth COM stone. 
Occasionally, COD partially dehydrates to COM and they coexist in kidney stones, a fact 
explained by the epitaxial relations and similarities between the two crystals [15] [16].  
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Also, COD is generally associated with an active growing stone, while COM defines a 
more stabilized stone. 
Calcium phosphate (CP) known as apatite, with its formula Ca10(PO4,CO3)6(OH,CO3), is 
a common mineral in nature and a very important component in bones and teeth. It 
appears as poorly crystallized in kidney stones and often forms the nucleus on which 
other minerals are deposited. The reported occurrence of apatite in kidney stones varies 
between 20-60% [8]. 
Calcium phosphate dehydrate (CPD) or brushite (CaHPO4·2H2O) is encountered in 
kidney stones less often than apatite, with a 2-4% occurrence [8]. It is a soft, silky 
mineral, usually honey-brown, showing a fine radial fibrous structure.  
Uric acid (UA), C5H4N4O3, appears in stones when the body breaks down purine 
nucleotides. It was the first kidney stone component to be described. It is present in about 
10% of all kidney stones [14] and is associated with low pH values in urine. An increase 
of urinary pH above approximately 6.5 is shown to decrease UA stones recurrences. 
Magnesium ammonium phosphate hexahydrate (MAP) or struvite (MgNH4PO4·6H2O) is 
associated with alkaline urine and is generally difficult to treat.  It occurs with urinary 
infections caused by urea splitting organisms like Proteus Sp. or Klebsiella Sp. It tends to 
grow quickly and to occupy the structures of the renal pelvis, the reason that it often 
presents as staghorn calculi [3] [17]. 
Cystine (CYS) was isolated from a urinary calculus in 1810 and it was also the first 
known amino acid. Even though cystine, as a kidney stone component, is reported to 
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occur in only 0.5% of all cases, cystine stones are known to have the highest recurrence 
rate of all urinary stones, both with and without recurrence-prevention strategies [3]. 
1.5.2 Underlying conditions in urolithiasis 
Extensive research has been directed towards identifying the conditions leading to stone 
formation and growth. Under normal circumstances, urine will not contain solid particles 
[3].  Calcium, as the main constituent of mineral compounds in kidney stones, is 
absorbed through the intestinal wall and deposited mainly in bones as apatite crystals. 
Calcium follows a continuous process of deposition and release from the bone matrix. At 
the renal level, calcium is filtered and reabsorbed in the normal urine formation process. 
Abnormalities, such as hyperparathyroidism, can lead to osteopenia with consequent 
pathologic fractures and nephrolithiasis due to an increase in urinary calcium filtration. 
Alternatively, any intestinal condition leading to an increased calcium and oxalates 
absorption can eventually translate into a urinary supersaturation in oxalates and calcium. 
Notable is that high urine concentrations in calcium and oxalates, and the resulting stone 
formation, has in most cases no apparent underlying cause and appears rather as 
idiopathic, related probably only to specific diet habits [7]. Citrates, as natural inhibitors 
in calcium crystallization, may also be present in low concentration in urine due to states 
related to loss of alkali in diarrhea or any other cause of metabolic acidosis [7].  
In the case of calcium phosphate stones, the associated high urinary pH is regarded as a 
main risk factor. Interestingly, by an unknown mechanism [7], the urinary pH continues 
to rise as the concentration of calcium apatite in the formed stones is increasing, even 
under normal metabolic conditions (normal levels of bicarbonate in blood). Fluids, 
12 
 
thiazide diuretics may be attempted, but administration of potassium citrate can further 
increase urinary pH and thus must be carefully controlled. 
Uric acid exists in equilibrium with urate as long as the urinary pH stays above 5.5. 
Hyperuricosuria, acidic urine pH or both are the main contributors in uric acid 
precipitation [3] [7]. Hyperuricosuria, occurring in gout or other conditions leading to 
hyperuricaemia, is not an essential factor in uric acid stone formation as these stones 
develop easily when urinary pH is lower than 5.5 with no uric acid metabolism 
abnormality. 
Normally, infectious stones are not associated with metabolic abnormalities [8] but 
chronic recurrent urinary infections with Proteus Sp., some Klebsiella Sp. and even 
Pseudomonas Sp. lead to formation of large amounts of ammonium from urea and a 
resulting high urinary pH, thus helping in struvite crystallization. The high bicarbonate in 
urine also determines high carbonate concentrations and ideal conditions for calcium 
phosphate association with struvite in these stones [8]. In many cases struvite can be 
followed or replaced by other stone constituents [17] that make it a possible constituent to 
be found in the core as the start point in mixed stone formation.  
Cystinuria, an autosomal recessive disease, is known to determine defects in renal and 
intestinal transport of amino acids like cystine, ornithine, lysine and arginine. Cystine is 
relatively insoluble which results in supersaturating of urine with cystine and stone 
formation. Medical management is usually not effective in cystine stones and most 
patients continue to redevelop stones and to undergo repetitive surgical procedures to 
have their calculi removed [3]. 
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1.5.3 Current composition analysis techniques 
Considered one of the most accurate composition analysis techniques [14], x-ray 
diffractometry (XRD) uses crushed stone samples for analysis and is based on 
comparison of standard diffraction patterns given by minerals most commonly found in 
kidney stones and expressed as interplanar d-spacing in Ångstroms with the  diffraction 
patterns resulted from the actual stone sample. It is considered very accurate for 
determining the bulk mineral composition in kidney stones, but its limitations are the use 
of low energy x-rays (8 KeV) which are unable to pass through intact stones and 
therefore requires stone pulverization, inadequate sensitivity when a limited amount of 
sample is available [3], and high operation costs [14].  
Infrared spectroscopy (IRS) also analyzes powdered samples of kidney stone and is based 
on the atomic vibration generated when infrared light interacts with the molecules in 
stone components [3]. The results are determined from predetermined material-specific 
energy bands in the absorption spectrum which are compared with standard absorption 
spectra from a set of calibration standards.  These infrared patterns are reported as a 
function of wave number (wavelengths in units of cm-1) corresponding to electronic 
vibrations in molecules.  IRS is frequently used in kidney stone bulk composition 
analyses because it is quick, can deal with very small samples, and is inexpensive. 
Disadvantages are related to long preparation times (often manual stone pulverization) 
and low capacity of differentiating between uric acid and calcium phosphates, or between 
small concentrations of COD in COM or the reverse [14].  
Microscopic examination of kidney stones (including polarized microscopy), although 
frequently used in urinary calculi analyses, is based on the assumption that all mineral 
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components have the same appearance all the time no matter the differences in mineral 
association or urine chemistry, which is not a sound assumption [3]. Stones are initially 
fragmented to reveal the internal structure, and then samples are taken from different 
parts of the stone for visual inspection and microscopic identification. It is inexpensive, 
allows for quick examinations, but requires high subjective experience and presents some 
difficulties in differentiating uric acid and purine derivatives from calcium phosphates 
[14].  
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Table 1 synthesizes some positive features and limitations of the three stone composition 
analysis techniques described above.  
Analysis method Advantages Disadvantages 
1. X-ray diffractometry (XRD) -easy preparation -bulk composition, no core details 
  -automatic measurements -noncrystalline materials not detectable 
  -quantitative analysis -high costs 
  
-possible exact component    
  differentiation   
2. Infrared spectroscopy (IRS) -moderate costs -bulk composition, no core details 
  -very quick examination -time consuming preparation 
  
-small sample examination  
  possible -some components difficult to differentiate 
  -semiautomatic measurements   
  
-noncrystaline materials  
  detectable   
3. Polarized microscopy -cost efficient -high subjective experience necessary  
  -quick examination 
 
-some components difficult to differentiate 
  
-small samples possible to  
  examine -quantitative analysis difficult in mixtures 
Table 1.Advantages and disadvantages of current kidney stone composition analysis 
techniques [14]. 
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1.6 Urolithiasis-cost of care and social impact 
 Urinary stones are passed with no intervention in 90% of patients if their diameter is 
below 5mm. This spontaneous passage occurs in only 50% of cases if stone diameter is 
between 5-10 mm, while stones larger than 10 mm in diameter generally require surgical 
intervention [18]. Extracorporeal shockwave lithotripsy (ESWL) is considered the 
method of choice in treating simple renal and proximal ureteral calculi that fail to pass 
spontaneously. Ureteroscopy is preferred for distal ureteral stones, while percutaneous 
nephrolithotomy (PCNL) is reserved for complex renal calculi or when ESWL has failed 
or is contraindicated [19].  All of these therapeutic interventions are expensive with 
variable success rates depending on stone’s size, location and composition, on patient’s 
anatomical features and underlying conditions. One study has found ESWL to result in a 
lower success rate (70%) than PCNL (96%) with total costs of treatment of about $2,700 
per case for ESWL and $4,100 for PCNL [6].  Annual rates of treatment have been on the 
rise, with a study in Quebec Canada showing a 59% increase in the number of patients 
undergoing at least one stone removal procedure over an 8 year period, with provincial 
total costs of $10.3 million in 1992 [20]. At the same time the annual cost of treatment in 
the United States was $1.83 billion in 1993 [18].  
Medical management and secondary prevention of urinary stones was the main topic for 
both clinicians and researchers over the last years. Study results vary upon the cost and 
efficiency of medical management of urinary calculi. It is generally believed that medical 
management of the first stone would not be cost effective [11] [18].  However, secondary 
prevention through general and stone-specific dietary measures, as well as certain types 
of medication, have been shown to significantly reduce recurrence rates [8] [12].  Over a 
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period of five years, the total per-patient costs for urinary calculi medical management  
(non-surgical) including initial and follow-up visits, imaging procedures and drug 
expenses, vary from approximately $1,400 in Canada and Turkey, $4,000 in Italy and 
Sweden, and over $8,000 in the United States [18]. These costs are comparable to that of 
a single surgical procedure for urinary stones removal. 
 
1.7 A New Imaging-Based Technology: Coherent scatter 
computed tomography (CSCT) 
Coherent scatter of diagnostic x-rays was firstly described by G. Harding. He explained 
the theory of coherent scattering and emphasized the importance of x-ray coherent 
scattering, generally neglected for imaging purposes, and its fundamental importance for 
determining the material structure [21]. Coherent scatter computed tomography (CSCT) 
is a new imaging-based tool being developed in our laboratory that has potential for 
laboratory composition analyses of intact kidney stones [22] [23] [24] [25].  CSCT is 
based on a material-specific analysis of coherent scatter and associated diffraction of 
diagnostic x rays.  The 70 kV x rays pass through a series of 3 x-y collimators to generate 
a pencil beam of about 1.5 mm2.  Between the second and third pair of collimators the 
beam passes a 0.30 g/cm2 gadolinium (Z=64) filter for blur reduction. The stone sample 
is scanned meticulously, depending on the size and number of fragments, using 32 to 40 
translations (covering the stone holder 2.5-cm diameter), 32 to 64 rotations and between 
1 and 5 elevations. The number of elevations is given by the ratio between the height of 
the largest stone to be scanned and the height of the x-ray beam. A beam stop device is 
placed in front of an image intensifier, thus impeding the transmitted primary beam, 
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while the images of the resulting scattered rays at angles between approximately 0.5 and 
10 degrees are acquired and converted into digital data.  X-ray scatter produces a scatter 
pattern specific to each material due to diffraction of the x rays in the specimen.  The 
scatter patterns from pure samples of the components found in urinary calculi are used to 
create a library of basis materials and used to identify the materials present in 
tomographic reconstructions of the stones and stone fragments. Seven of the most 
represented minerals in kidney stones were used as basis materials: whewellite (calcium 
oxalate monohydrate-COM), weddellite (calcium oxalate dehydrate-COD), apatite 
(calcium phosphate-CP), brushite (calcium phosphate dehydrate-CPD), uric acid (UA), 
struvite (magnesium ammonium phosphate-MAP) and cystine (CYS). The bases used in 
CSCT analysis are (except COD) pure, commercially available compounds (Sigma 
Aldrich Inc. and Fluka Chemie AG). Calcium oxalate dihydrate is represented by a 
powdered kidney stone reported by Infrared Spectroscopy (IRS) to contain at least 99% 
COD.     
Each CSCT acquired scatter pattern is sectioned into concentric annuli due to its 
circularly symmetric nature. The signal in each ring is integrated and normalized by the 
solid angle corresponding to that particular ring, resulting in a cross-section curve. 
Composition analysis is performed by examining the coherent-scatter cross-sections in 
each pixel using a non-negative least squares (NNLS) regression. The measured cross-
sections in each pixel is decomposed into its constituents, from which material specific 
maps are constructed. Images for each component are reconstructed using filtered back-
projection reconstruction. 
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The composition analysis reports mineral concentrations both as grams/cm3 and mass 
percentages relative to the entire stone. The reconstructed images identify the exact 
location of each mineral within the stone for each separate elevation. Figure 5 
exemplifies clearly how CSCT identifies the location of different materials placed in 
different circular enclosures in a phantom made of polymethylmethacrylate (PMMA) 
containing pure minerals commonly found in the composition of kidney stones: A) CT 
image of the phantom; and B) to H) CSCT reconstructed images of COM, CP, CPD, 
PMMA, CYS, UA and MAP.  Fields G) and H) also show that minerals, in this case UA 
and MAP, are exactly identified both as standalone materials and in mixture (circled 
enclosure). The two top enclosures on the left column contained air only and CSCT did 
not report a material in them. 
    
Figure 5.CSCT reconstructed images of a phantom containing several minerals in 
pure form or mixture. 
The seven basis minerals used in CSCT material analysis are the most frequently found 
minerals in kidney stone composition determined by currently accepted techniques. It is a 
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real possibility that other minerals may also be present in kidney stones. We make the 
likely assumption that, since there is no basis scatter pattern for those materials in the 
CSCT calibration set, they will rather not be reported by CSCT than being miss-reported 
as one of the seven CSCT basis materials. Even if, as it will be shown later in the thesis, 
some basis scatter patterns present certain similarities with others, they always express 
differences as well. As shown in the above phantom experiment, CSCT succeeds in 
differentiating between minerals even in situations where their basis patterns are similar. 
It is unlikely that minerals not included in the calibration set of basis, would generate 
patterns identical with those from the CSCT basis minerals, and so they would not be 
reported by CSCT as one of the basis minerals.  
1.8 Research Objectives 
Strategies to reduce recurrence rates are an established component of patient management 
programs in most developed societies.   
In the light of recent years advanced knowledge related to the multi-mineral composition 
of a large majority of the kidney stones, demonstrated associations or causative relations 
with major metabolic and genetic disorders [26] [27] [28] and recent research revealing 
that sustained and complex recurrence prevention programs may be effective,  an 
imaging approach for non-destructive composition analysis of urinary calculi may 
contribute to a further reduction of kidney stone recurrence rate. 
While well established, effective recurrence prevention programs are now employed in 
clinical settings, prolonging the time between episodes effective [29], studies show that 
overall recurrence rates remain at between 20% and 80% [2] [10] [11] [29].  One factor 
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that may be responsible for the continuing recurrences is that the laboratory methods of 
analysis described above provide bulk measures of mineral components and do not target 
the particular component at the core of the stone where nucleation was initiated.  It is 
known that this core may be a small fraction of the total stone mass, and hence there is a 
concern that bulk measures do not have the sensitivity to report the core component.  In 
addition, even if reported, these methods cannot make a distinction between a small but 
concentrated core of a particular component, or a distributed low concentration of the 
same component.  
The goal of this research is to evaluate CSCT, the new imaging-based technology 
developed in our laboratory, for identifying where different material components may be 
distributed throughout an intact stone or large fragment.  The implication is that if 
successful, a medical and dietary prophylaxis designed with both the specific component 
at the stone core as well as in outer layers might help reduce the recurrence rate of kidney 
stone disease. 
The specific objectives are: 
1) Conduct a clinical evaluation of CSCT on intact kidney stones and fragments 
from approximately 100 patients undergoing stone removal.  Stone samples are 
examined (non-destructively) using CSCT and then submitted for conventional 
IRS analysis. 
2) Compare bulk composition (mass fraction) of stone components reported by 
CSCT with IRS. 
3) Determine composition of central core of stone as reported by CSCT, and 
determine whether IRS is reporting the same material in its bulk analysis. 
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These objectives are addressed in Chapter 2 of the thesis, consisting of a manuscript 
submitted to Radiology for publication. 
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Chapter 2  
2 Prospective Clinical Study of Coherent-Scatter Computed 
Tomography for Laboratory Composition Analysis of 
Kidney Stones 
 
2.1 Introduction 
Prevalence of urinary calculi is between 5% and 12% depending on age, gender, climate 
and race [3] [6] [29], with an annual incidence rate of 0.5% in North America and Europe 
[5] and a lifetime recurrence rate with no prevention strategy varying from 50% to 80% 
[2] [5] [8] [10] [11] [29]. The number of recurrences is reduced in various degrees in the 
presence of certain medical and dietary prevention plans [29].  
Most urinary calculi are calcium-based [8]. Stones made of struvite, cystine or uric acid 
are associated with certain medical conditions and occur less frequently, as shown in 
Table 2.  
Crystal Abbreviation Frequency (%) Association 
Calcium oxalate monohydrate COM 40-60 Metabolic abnormalities 
Calcium oxalate dihydrate COD 40-60 or idiopathic  
Calcium phosphate                         CP 20-60   
Calcium phosphate dihydrate CPD 2-4   
Uric acid UA 5-10 Hyperuricaemia, hyperuricosuria 
Struvite MAP 5-15 Urinary infection 
Cystine CYS 1-2.5 Cystinuria 
Table 2.Common kidney stone components. 
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Many small stones are spontaneously eliminated but larger ones need fragmentation or 
removal by surgical interventions. A shift to less invasive, outpatient treatment modalities 
as a result of technological progress has been recorded in recent years, perhaps following 
an important increase in prevalence [29]. Recurrence prevention through diet and 
medication remains an important part of patient management and often very effective 
[13] [18].  
Kidney stones are formed by various processes that include nucleation, aggregation and 
epitaxy, and often have a complex structure consisting of a core and one or more shells 
[16]. It is generally accepted that stone composition, and in particular the nucleating 
event, is an important indicator of stone etiology and a major factor in management of 
urolithiasis [1] [28]. However, stones are typically fragmented before removal and 
normal laboratory tests of composition, based on infrared spectroscopy (IRS) and x-ray 
diffractometry (XRD) involve pulverizing the stone [3]. For both of these reasons it is 
difficult to determine the specific composition of the initial core. 
We are developing a new analysis tool called coherent scatter computed tomography 
(CSCT) that combines the strenghts of diffraction analyses with the benefits of 
tomographic imaging to determine distribution images of various mineral components in 
intact stones and stone fragments. The imaging capabilities of CSCT and preliminary 
stone analysis results have been previously reported [22] [23] [24] [25].  
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2.2 Objectives 
The main objective of this work is to evaluate CSCT as a laboratory technique for 
structural and compositional analysis of intact kidney stones in a clinical study and to 
compare the results with IRS. Laboratory IRS has been shown to correctly identify 
minerals in the samples it has to work with [3] [28], and therefore we hypothesize that 
CSCT provides composition analysis results equivalent to IRS for identifying the most 
prevalent component in each sample while also revealing structural details and 
identification of the central core component.  
Our goal is to evaluate the potential of CSCT as a method for stone analysis, and to 
highlight the importance of adopting an imaging-based approach for material analysis 
laboratory tests.  
 
2.3 Material and methods 
2.3.1 CSCT analysis 
The CSCT system was design and constructed in our laboratory using a conventional x-
ray tube and image detector [22] [23] [24] [25]. Scans use 70 kV x-rays, collimated to an 
approximately 1.25-mm square beam and passed through a gadolinium filter to reduce 
the energy spread of photons in the beam.  A total of either 32 or 64 projections 
(depending on specimen size) were obtained covering an angular range of 180 degrees 
using first-generation CT geometry.  Each projection consisted of 40 projection 
measurements at 0.63-mm center-to-center spacing, resulting in reconstructed images 
with 0.63-mm pixels, a 25-mm field of view, and 1.5-mm slice thickness. 
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The beam passes through intact calculi securely mounted on a stage that allows multiple 
elevations, translations and rotations. The emergent low-angle (0.5 to 10 degrees) 
scattered x-rays generate material-specific scatter patterns captured using an image 
intensifier and CCD (charge-coupled device) camera (Figure 6).  
 
Figure 6. Schematic diagram of CSCT device. The scattered x-rays at angles 
between 0.5 and 10 degrees are collected and further analyzed for computed image 
reconstruction. 
A material analysis of each pattern is performed by comparison with a set of scatter 
patterns generated by pure samples of minerals listed in Table 1. These are symmetric 
patterns with clear, well defined rings of various scatter intensities (Figure 7).  
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Figure 7.Example of basis scatter patterns of common kidney stone minerals. 
Unlike other materials available in commercial form, a pulverized kidney stone identified 
by IRS as at least 99% COD was used to generate the specific scatter pattern for this 
mineral. In addition, COD generates a polycrystalline diffraction pattern containing 
multiple bright spots as observed in Figure 8 (left). The COD powder diffraction pattern 
was estimated by rotating the sample continuously during data acquisition, producing the 
pattern shown in Figure 8 (right).     
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Figure 8. COD-static, polycrystalline scatter pattern with bright spots and poorly 
expressed diffraction rings (left), and COD-rotated, powder scatter pattern with 
uniform, well defined scatter rings (right). 
The mass of each component material was determined for a range of positions and angles 
and used to reconstruct tomographic images of the distribution of each component in 
slices at multiple levels through the stone. The physical and mathematical approach of 
CSCT was previously described by Davidson et al [25]. While CSCT analysis provides 
the concentration of each component in g/cm3, these were converted to mass percentages 
of the entire stone in order to compare them with IRS. 
 
2.3.2 Measurement errors and uncertainties in CSCT analysis 
The diffraction-pattern peaks produced by CSCT are broader than XRD due to the use of 
a diagnostic x-ray spectrum and may partially overlap. This problem is similar to that 
encountered by IRS [31], and we use a similar method of fitting the measured patterns to 
a set of calibration standards.  
Five repeated scans were performed on capsules containing pure samples of each basis 
material in PMMA containers to assess the analysis precision. Each scan generated a set 
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of material-specific images that were analyzed for composition using the whole set of 
seven basis stone scatter patterns plus PMMA. The results were used to generate a 
response matrix describing the tendency for one material to be miss-identified as a 
different material.  The response matrix was used to apply a correction for the miss-
identification, although this correction affects only a couple of material combinations as 
described in the results section, and the correction was never more than 13%. 
This experiment is limited to the situations in which the measured component is highly 
represented in the stone composition, with any of the other measured materials being 
present in very low proportions. For a thorough results correction in combinations of 
various proportions of materials in a kidney stone, a much larger experiment is needed. In 
the design of such an experiment all possible combinations of two or more components 
must be taken into consideration.      
The precision of each measurement is determined primarily by the propagation of x-ray 
quantum statistics through image reconstruction and material analyses.  Since the number 
of x-ray quanta in each pattern is proportional to the mass of the scattering sample, we 
make the likely assumption that the statistical variance in each measurement is 
proportional to the mass of the scattering material.  For example, if repeated 
(independent) CSCT measurements of the mass of material j, mj, have a variance , 
then we are assuming that the normalized variance, 	 
, is independent of  and can 
be measured and used as a known quantity to estimate the uncertainty in any subsequent 
measurement.  That is, 
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 
   .         (1) 
For a specimen with multiple components, we make the assumption that the addition of 
cross terms results in an approximate estimate of the uncertainty, giving 
  ∑               (2) 
summed over all materials i in the material analysis, and where the quantities in square 
brackets, called the normalized material cross-covariance matrix, are measured and 
tabulated for the particular test conditions.  Terms in the normalized cross-covariance 
matrix describe random mean-square fluctuations in the computation of material j for a 
measurement on physical material i, averaged over k repeated scans. Thus, each term is 
defined by: 

      ∑               (3) 
 
2.3.3 Effect of stone pulverization on material analysis 
Unlike IRS, CSCT uses intact kidney stones or fragments. To observe whether 
pulverization influences analysis results, a set of stones were scanned by CSCT in both 
intact and pulverized forms. Following the CSCT scan in intact form, each stone was 
crushed to a fine powder using a laboratory mortar and pestle for 5 minutes, then 
encapsulated in standard, pharmaceutical gelatin capsules for the second scan. A baseline 
31 
 
scan of an empty capsule was subtracted from the analysis results. The x-ray energy and 
number of angular projections and elevations were identical for each scan. 
 
2.3.4 Comparison of CSCT and IRS for bulk composition analyses 
A prospective clinical evaluation of CSCT was initiated in the Imaging Research 
Laboratories of the Robarts Research Institute with the Department of Urology at St. 
Joseph’s Health Center. It was performed over a four year period and included 119 
patients diagnosed with urolithiasis. All ethics approvals were obtained as necessary and 
patients signed a written informed consent. Stones collected through uretheroscopy or 
percutaneous nephrolithotomy were scanned and analyzed by CSCT, then sent to an 
external laboratory for IRS. The CSCT and IRS results were evaluated in terms of 
agreement for primary mineral component detected by the two methods and their ability 
to identify and determine the proportion of the core mineral. 
 
2.4 Results 
 
2.4.1 CSCT material analysis 
Figure 9 shows the scatter patterns for the minerals described in Table 2. These basis 
patterns were used in the CSCT material analysis to calculate the mineral concentration 
in each projection measurement, and filtered back-projection methods were used to 
reconstruct mineral-specific images of each component. 
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Figure 9. Scatter patterns of common kidney stone minerals. Each pattern consists 
of peaks superimposed on a background continuum.  Similarities are observed in 
some peaks between patterns generated by MAP and CPD and by COD and COM. 
UA, CP and CYS show clearer distinction in their patterns. 
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Figure 10 shows the material-analysis result for a typical specimen consisting of one 
intact and one fragmented kidney stone. In these images, brightness corresponds to mass 
concentration (g/cm3) of the two identified components (COD and COM) at each pixel 
location in one tomographic slice.  Several slices were acquired to cover the entire 
volume of the specimen.  The total mass of each component is reported in grams and 
converted to mass percentage of the entire stone.  In this particular example, CSCT 
reported 80% COM and 20% COD while IRS reported the same sample as 90% COM  
and 10% COD.  These two results are most likely within experimental error, but the IRS 
result misses the fact that the intact stone (left) clearly has a small COD core while all of 
the COM is in an outer layer.  The other stone, fragmented into three pieces, likely has a 
similar composition as one fragment in particular (lower) shows a distinct central region 
of COD.  Thus, rather than assuming the COD is a minor component in the analysis, the 
CSCT result clearly indicates that any prevention strategy should specifically target 
COD.  In this case that would not likely impact on patient management. 
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Figure 10. Example of CSCT analysis and mineral-specific image reconstruction 
showing an intact stone (left side of each image) and three stone fragments from the 
same patient. 
 
2.4.2 Measurement errors and uncertainties in CSCT analysis 
The composition analysis results for each basis material are summarized in Table 3.  
Each row describes the total mass of each reported material from the analysis of a pure 
specimen, normalized to 100% on the diagonal members.  Thus, for example, the pure 
182 g COD sample was reported as 182 g COD plus a miss-identification of 24 g (13% of 
182 g) of COM.  The pure COM specimen was reported as COM plus very small 
concentrations of other materials. 
This data shows that COM, CP, CPD and CYS are all reported accurately with only very 
minor possible miss-identifications (<4%) of other materials.  COD results in an 
additional 13% COM and 5% MAP.  UA results in an additional 8% CYS and MAP 
35 
 
results in an additional 11% CPD and 8% CYS.  These miss-identifications are reduced 
to less than 1% after correction by the response matrix. 
               Reported materials (% g/cm3)                                                          
   COD  COM  CP  CPD  UA  MAP  CYS  
 COD, 182 g  100 13 2 2 0 5 3 
 COM, 492 g 2 100 2 0  1 1 2 
Physical CP, 302 g 0 0  100 0  1  0  1 
sample  CPD, 477 g 1 0  2 100 2 2 1 
 UA, 289 g 0  1 2 2 100 3 8 
 MAP, 152 g 0  0 2 11 4 100 8 
 CYS, 543 g 0  1 0  2 4 2 100 
Table 3. The response matrix shows the reported proportions of materials (rows) for 
each each pure physical sample being analyzed (colums), averaged over five 
repeated CSCT scans. Each row is normalized by the diagonal element. For 
example, the top row indicates that a pure, 100 g COD is reported to consist of 100 g 
of COD plus 13 g of COM, 2 g of CP, 2 g of CPD, 5 g of MAP and 3 g of CYS. 
The normalized cross-covariance matrix is shown in Table 4.  For illustration, the 
statistical variance in a measurement of COD in a sample consisting of 200 g COD plus 
50 g COM, using Eq. (2), is estimated as 
   1.53%  200 (  0.18%  50  315 
corresponding to an RMS uncertainty in the COD measurement of 18 g (9%).  
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               Reported materials (% g/cm3)                                                           
   COD  COM  CP  CPD  UA  MAP  CYS  
 COD  1.53 -1.03 -0.24 0.44 -0.03 0.40 0.12 
 COM  -0.18 0.42 -0.15 -0.05 0.13 -0.03 0.11 
Physical CP  0.00 0.00 0.10 0.00 -0.01 0.00 0.00 
material  CPD  -0.49 0.02 -0.20 0.98 0.05 -0.34 0.12 
 UA  0.02 -0.05 0.08 0.07 0.13 -0.15 -0.19 
 MAP  0.11 0.15 0.19 -4.10 0.96 8.40 -0.74 
 CYS  0.08 0.03 0.03 0.09 -0.52 -0.05 0.69 
Table 4. The cross-covariance matrix shows the statistical variance and cross 
covariance terms between reported materials (rows) for pure physical samples 
(columns), normalized by the concentration (g/cm3) of the pure sample. 
It should be noted that some cross terms are negative.  For example, COD and COM are 
negatively correlated which means that in any one individual analysis, an increase in a 
reported COD amount is correlated with a decrease in the COM amount.  This is a 
consequence of the two scatter patterns being similar.  Patterns that differ greatly, such as 
CP and CYS, have a very small cross term. 
 
2.4.3 Effect of stone pulverization on material analysis 
The composition analysis results obtained from a set of kidney stones scanned in both 
intact and pulverized form were compared for agreement using Bland-Altman plots [32] 
[33].  
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Figure 11. Bland-Altman plots suggest a strong agreement between CSCT analysis 
results of kidney stones in intact and powdered form. The mean difference is shown 
as dotted line. Both COM and COD were combined in the calcium oxalate results. 
The vertical axes show the difference between CSCT intact and CSCT powdered, 
while the horizontal axes represent the average between the two sets of results. MAP 
and CPD were not well represented due to a small sample size. 
 
As shown in Figure 11, good agreement between the two sets of results was observed, all 
differences being less than 15% and most less than 5% of the mean, independent of their 
low or high proportion in the stone. Similar agreement was observed with the IRS results. 
It was therefore concluded that crushing the stones to fine powder had, by itself, no 
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influence over CSCT analysis results, but the draw-back for stone pulverization is the 
loss of all structural details available with CSCT scanning intact calculi (Figure 12). 
    
Figure 12. Kidney stones scanned by CSCT in intact form (left) with obvious 
CP+COM core surrounded by COD. Same stones scanned in powdered form (right) 
show same materials but also the loss of structural details. 
 
2.4.4 Comparison of CSCT and IRS for bulk composition analysis 
From a total of 119 patients, 34 either withdrew from the study, had no stone at the time 
of surgery, or their stone fragments were too small (<1 mm) to be scanned by CSCT.  
IRS has reported most stones as having one or two components. At the same time CSCT 
reported one, two and sometimes three minerals in stones. The analysis results reported 
by CSCT were corrected using the response matrix.  Calcium oxalate based minerals 
(COD and COM) were considered as one group having, from a clinical point of view, 
identical strategies of recurrence prevention, unlike MAP, UA, CYS, CP and CPD that 
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generally have different recurrence prevention strategies.  We used the terms of primary 
and secondary mineral to define the two minerals with the highest proportions reported in 
the composition analysis. In this respect, in 74 of 85 patients (87%) IRS and CSCT both 
reported the same primary materials.  In 28 patients (33%) the primary and secondary 
minerals found by both methods were identical. In 3 patients, IRS and CSCT found 
different minerals to be the primary and secondary components in the stone composition. 
It is possible these differences may be related to sampling issues associated with stone 
pulverization and preparation preceding IRS.  
CSCT image reconstruction found only a small number of stones to not express a classic 
“core & shell” structure, but rather a uniform geometry. On the other hand, IRS reported 
more than half the stones as containing only one mineral. As a result, in 35 patients 
(41%)  CSCT reported a core material that was not found by IRS. In terms of core 
imaging and core composition CSCT was able to reveal the internal structure of intact 
kidney stones whether a distinct core existed or the stones were made of uniform mineral 
mixtures (Figure 13). 
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Figure 13. Examples of CSCT reconstructed images: stones with clear "core and 
shell" structure (above) and stones with more uniform, homogenous structure and 
no evident core (bellow). 
 
2.5 Discussion 
As a laboratory based, imaging technique, CSCT is a novel method of imaging the 
structure and determining the mineral composition at the core of intact kidney stones.  If, 
as is generally accepted, a core-targeted recurrence prevention approach will be 
employed for recurrence reduction in stone formers, CSCT has the potential to become an 
important tool of choice in composition analysis of urinary calculi.  In 52 patients (61%), 
the addition of supplementary measures in their recurrence prevention strategy may have 
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had an impact on their recurrences, since various amounts of MAP, UA, CYS and even 
calcium based minerals have been detected by CSCT and not reported by IRS. 
The good agreement recorded between CSCT intact versus CSCT powdered on stone 
composition analysis shows that the analysis of intact kidney stones is possible and 
reliable.  Pulverization, necessary for conventional IRS and XRD analysis methods, does 
not change analysis results but destroys the stone’s geometry and the internal structure 
hence losing important information on core composition and limiting recurrence 
prevention to target only bulk composition results.  
Despite scatter pattern similarities between COD and COM, CSCT demonstrates the 
ability to differentiate between them in the analysis, although from a clinical perspective, 
this differentiation is less important due to identical prevention protocols for calcium 
oxalate stones and the natural tendency of COD to transform into the more stable COM 
[34].  
As expected, most stones in this study were calcium based with various associations 
between calcium oxalates and calcium phosphates.  Many cystine stones were found to be 
uniform and not associated with other minerals.  Common associations between all forms 
of calcium based minerals were found.  Interestingly, MAP was detected in a number of 
stones as a secondary mineral and mostly as a core component. Even if MAP is known to 
occur in urinary infections related to urea splitting organisms such as Proteus Sp., it was 
shown before that all urinary stone constituents could join MAP in kidney stones [17]. 
We found 10 patients (12%) in which MAP was associated with UA, mostly with MAP 
as a core component.  One form of uric acid, ammonium acid urate, has been previously 
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reported to appear in association with MAP or in the context of urinary infections and an 
alkaline pH [17].  It remains to be established whether urinary infections may trigger the 
nucleation process with MAP crystallization and growth followed by the deposition of 
other minerals on the already form nucleus.  IRS missed the core mineral detected by 
CSCT in 35 patients (42%), which raises the question of whether these patients are 
missing the opportunity to have a core-targeted prevention plan to follow. 
Undoubtedly, medical and dietary recurrence prevention measures have proven their 
efficacy [29].  As stated before, general prevention measures such as an increase in the 
use of thiazide diuretics and urine alkalinisation with potassium citrate can be very 
effective in many cases. In this context, the possibility of further recurrence reduction 
using a core targeted approach emphasizes the real value of using CSCT as an imaging 
based composition analysis technique. 
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Chapter 3  
3 Conclusions and future work 
 
3.1 Conclusions 
 
3.1.1 CSCT reconstructed images for individualized stone 
characterization 
Coherent scatter computed tomography analysis provides structural information of stone 
core and its surrounding layers not reported by IRS.  The analysis of intact urinary calculi 
gives insight as to the arrangement of various mineral components within the stone, their 
intimate associations, offering at the same time the opportunity for interpretation of 
different pre-existing or co-existing metabolic conditions in stone formers. 
Both CSCT and IRS reported the same primary material (most prevalent) in 74 patients 
(87%).  This gives confidence that both CSCT and IRS are capable technologies.  The 
core component found by CSCT was missed by IRS in 41% of cases.  At the same time, 
when detected, the core mineral is reported by IRS only as part of the bulk composition 
analysis with no reference to its location within the stone. 
Structural details like “core and shell” stone structure are undoubtedly useful in planning 
a recurrence prevention strategy that targets the core mineral(s).  Moreover, this detailed 
information can also be valuable in deciding on treatment modality on repetitive stone 
formers, acknowledging that different minerals present different degrees of hardness and 
so different response to lithotripsy. In this regard, the development of data bases with 
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CSCT images of previous stones in highly recurrent patients may be helpful not only for 
comparison and research purposes, but also for rapid access and clinical decision making 
when these patients come to the clinic with relapses.  
 
3.1.2 CSCT an alternative to classic analysis techniques 
The agreement between CSCT and IRS on the main stone components demonstrates that 
both methods are technically accurate for composition analysis. The difference comes 
from IRS using one or several powdered samples from a stone, which can lead to 
sampling errors. When a surface sample is collected this may contain only limited 
amounts of core material depending on the size of the sample and the size of the core. 
In our study, CSCT has shown that kidney stones may often contain two or more 
components. They are following a classic “core and shell” structure with a core variable 
in size surrounded by layers of different minerals. Due to the IRS sampling issues 
mentioned before, not only the core material but also other stone components may be 
under-reported by IRS. As a result, by compensation, IRS reports higher proportions of 
the materials detected, which may lead to the belief that the analyzed stone has a uniform, 
single-mineral composition. In reality the lesser represented minerals may be of great 
importance in understanding the process of stone formation and, in many cases these 
minerals could explain why the recurrences in some patients occur more often than in 
others. 
In 61% of the study patients, CSCT reported the presence of a mineral not reported by 
IRS.  In most cases the missed mineral was the core component, while in other patients 
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the missed mineral was part of the structures surrounding the core. What is possibly more 
important is that these components were from different classes of minerals with respect to 
recurrence prevention measures and thus these patients could have had the option of a 
more complex recurrence prevention strategy. 
It is also true that some disorders, such as cystinuria, favors kidney stone recurrences. 
Even in these patients, if a core component different from cystine is detected, the patients 
can benefit from preventive measures targeted on that particular core component as a 
measure of trying to increase the stone-free period between stone episodes and spare the 
patients from numerous procedures. 
         
3.2 Clinical approach in future studies 
The examination of intact urinary calculi by CSCT analysis reveals the presence of 
minerals and their spatial arrangement in composition image maps. These composition 
maps and supplementary knowledge of the interrelationships between various structures 
in a stone may have a great impact on clinical decision making regarding recurrence 
prevention plans [22].  
Two stones from our clinical study reported by IRS as 100% cystine were imaged by 
CSCT to also contain a UA core surrounded by a layer of cystine. The proportions of UA 
were reported by CSCT at 12% and 14% respectively of the entire stone composition. 
This aspect shows how selected patients suffering of cystinuria, known as having 
frequent kidney stones recurrences and not many preventive options, may benefit from a 
recurrence prevention plan targeting UA presence and crystallization in urine. By 
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interfering with the nucleation process, the periods between recurrent stones episodes 
may be prolonged in these patients, with clear social and economic positive impact [23]. 
Social and economic aspects are not the only aspects of clinical management of recurrent 
urolithiasis. Clinical decisions are usually made based on patient and physician 
preferences, and efficacy or drawbacks of known therapeutic options. Although most 
patients are interested in preventing future episodes [18] it is their compliance we know 
little of. Ultimately, it is the patient desire, lifestyle and history of stone episodes that will 
indicate if a prophylaxis plan will be followed. 
Mixed kidney stones, especially the non-calcareous ones and knowledge of their 
structural arrangements have been shown to have strong interrelationships with 
determining the array of metabolic disturbances encountered in those patients [28]. In 
many cases the existent metabolic disorders help predict the composition of kidney stones 
in certain patients and vice versa. In this context CSCT composition-imaging analysis 
may prove of great help in the analysis of mixed stones, thus facilitating the diagnosis of 
particular metabolic diseases. 
A blinded, extended, future clinical trial, with a dual design, CSCT and IRS for 
composition analysis and in which patients will benefit of recurrence prevention 
strategies based on either analysis technique is now shown to be possible. Since CSCT 
and IRS analyses reveal equivalent results on major stone components with CSCT 
offering in addition detailed structural and compositional analysis, including the core, a 
future clinical study may demonstrate unequivocally clinical benefits of employing 
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image-based CSCT in the composition analysis of intact urinary calculi for recurrent 
stone formers. 
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Appendices 
Appendix A.Comparison data on 85 patients between CSCT results measured and 
CSCT results corrected for measurement response matrix (grams). 
  CSCT measured (grams)     CSCT corrected for measurement response matrix (grams) 
 
Patient 
# 
COD COM CP CPD UA MAP CYS  COD COM CP CPD UA MAP CYS 
1 4 0.19 0.07 0.50 0.17 0.24 1.83 1.09   0.19 0.05 0.50 0.00 0.13 1.82 0.92 
2 15 0.15 0.14 0.13 0.17 58.27 8.41 1.19   0.15 0.12 0.13 0.00 57.93 8.40 0.00 
3 17 1.22 2.08 4.85 0.59 7.77 3.92 36.70   1.22 1.92 4.85 0.17 6.19 3.86 35.77 
4 21 5.21 34.31 1.25 0.62 0.72 1.52 0.50   5.21 33.63 1.25 0.48 0.65 1.26 0.35 
5 23 7.35 47.67 4.60 1.44 1.51 1.35 0.74   7.35 46.71 4.60 1.33 1.45 0.98 0.54 
6 24 0.33 1.10 0.05 0.07 43.08 3.41 6.29   0.33 1.00 0.05 0.00 42.84 3.40 2.57 
7 25 1.21 1.27 53.11 0.65 5.28 1.68 1.22   1.21 1.11 53.11 0.48 5.19 1.62 0.67 
8 26 19.50 41.78 12.82 4.65 1.25 0.68 0.84   19.50 39.24 12.82 4.65 1.22 0.00 0.74 
9 27 21.90 31.24 3.40 1.57 2.04 2.58 1.20   21.90 28.39 3.40 1.41 1.94 1.49 0.92 
10 28 0.75 1.05 25.19 1.07 4.00 1.01 1.13   0.75 0.95 25.19 0.97 3.93 0.97 0.73 
11 29 1.00 1.59 24.58 77.84 4.87 1.58 4.69   1.00 1.46 24.58 77.67 4.64 1.53 4.18 
12 32 0.00 16.47 0.05 0.05 148.21 9.50 20.35   0.00 16.47 0.05 0.00 147.52 9.50 7.73 
13 33 3.17 61.21 3.87 1.18 2.17 2.50 0.90   3.17 60.79 3.87 0.93 2.05 2.34 0.54 
14 34 46.80 51.36 72.55 8.44 5.26 14.24 3.23   46.80 45.28 72.55 7.13 4.71 11.90 1.86 
15 35 37.69 30.84 20.62 4.30 1.65 10.52 1.91   37.69 25.94 20.62 3.35 1.26 8.64 1.08 
16 36 1.57 2.85 9.28 1.51 15.49 5.79 135.18   1.57 2.65 9.28 0.88 9.93 5.71 133.48 
17 37 22.05 99.68 12.79 5.43 1.58 7.69 3.53   22.05 96.82 12.79 4.71 1.20 6.58 2.88 
18 38 0.90 2.18 3.59 0.83 3.43 3.33 34.13   0.90 2.06 3.59 0.47 1.95 3.29 33.59 
19 39 2.14 34.75 4.06 5.21 3.99 4.67 3.60   2.14 34.48 4.06 4.71 3.69 4.56 2.92 
20 41 21.76 7.31 10.98 17.75 0.15 4.42 9.51   21.76 4.48 10.98 17.38 0.00 3.33 9.24 
21 42 26.48 10.05 1.01 13.21 32.70 1.86 20.49   26.48 6.61 1.01 13.15 31.96 0.54 17.83 
22 43 26.77 16.45 4.44 12.93 0.07 0.06 2.21   26.77 12.97 4.44 12.93 0.00 0.00 2.20 
23 45 14.43 8.13 0.77 9.86 13.56 0.35 11.15   14.43 6.26 0.77 9.86 13.16 0.00 10.07 
24 46 0.19 0.04 0.03 0.07 0.01 0.07 0.03   0.19 0.01 0.03 0.06 0.01 0.06 0.02 
25 47 15.52 13.88 13.73 7.98 4.82 3.34 2.69   15.52 11.86 13.73 7.70 4.63 2.56 2.10 
26 48 0.91 0.27 0.23 1.20 1.06 0.99 7.20   0.91 0.15 0.23 1.09 0.74 0.94 7.04 
27 49 10.71 22.59 0.68 1.68 2.11 2.29 0.82   10.71 21.20 0.68 1.48 2.02 1.75 0.51 
28 50 7.92 3.96 3.23 1.75 0.84 0.39 0.36   7.92 2.93 3.23 1.75 0.82 0.00 0.30 
29 51 0.36 0.37 1.36 0.47 5.73 1.14 30.31   0.36 0.33 1.36 0.35 4.50 1.12 29.76 
30 52 1.27 0.23 0.89 23.54 0.43 1.50 0.72   1.27 0.07 0.89 23.38 0.35 1.43 0.57 
31 53 0.35 0.32 0.71 0.51 2.88 4.68 55.36   0.35 0.27 0.71 0.00 0.51 4.67 54.76 
32 54 4.50 20.05 0.20 1.39 1.42 1.27 0.77   4.50 19.46 0.20 1.27 1.36 1.05 0.57 
33 55 0.63 0.63 6.73 84.87 0.29 1.79 5.48   0.63 0.55 6.73 84.68 0.01 1.75 5.32 
34 57 1.14 10.00 5.87 1.61 5.04 1.32 1.56   1.14 9.85 5.87 1.47 4.95 1.26 1.05 
35 58 0.09 1.20 0.09 0.10 1.52 1.61 23.57   0.09 0.18 0.09 0.00 0.52 1.69 23.31 
36 60 15.25 73.40 0.68 5.73 4.59 6.89 3.50   15.25 71.41 0.68 5.05 4.24 6.13 2.64 
37 61 9.82 5.03 2.05 1.39 0.84 1.97 1.27   9.82 3.76 2.05 1.22 0.73 1.48 1.08 
38 62 20.90 9.93 3.28 2.51 1.97 1.79 1.08   20.90 7.21 3.28 2.43 1.90 0.74 0.86 
39 63 21.20 29.53 0.23 2.18 37.68 6.90 1.24   21.20 26.77 0.23 1.54 37.45 5.84 0.00 
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40 64 3.27 20.58 3.50 1.11 2.40 1.38 0.53   3.27 20.15 3.50 0.98 2.34 1.21 0.24 
41 65 1.58 22.47 0.09 0.57 17.33 6.21 1.30   1.58 22.26 0.09 0.00 17.09 6.13 0.00 
42 66 4.49 22.19 0.37 0.72 0.82 0.91 0.54   4.49 21.61 0.37 0.65 0.78 0.68 0.42 
43 67 2.56 1.41 9.44 1.57 4.59 2.65 1.17   2.56 1.07 9.44 1.30 4.47 2.52 0.06 
44 68 6.50 25.72 0.34 0.79 1.27 1.77 0.79   6.50 24.87 0.34 0.63 1.19 1.45 0.57 
45 69 0.20 0.34 0.05 0.10 29.67 10.09 1.81   0.20 0.31 0.05 0.00 29.27 10.08 0.00 
46 70 2.46 5.24 0.28 0.53 0.94 0.85 0.48   2.46 4.92 0.28 0.45 0.90 0.73 0.34 
47 71 1.00 7.49 0.16 0.39 110.47 41.18 6.26   1.00 7.36 0.16 0.00 108.82 41.13 0.00 
48 72 0.22 0.06 0.02 0.09 7.21 3.96 1.01   0.22 0.03 0.02 0.00 7.05 3.94 0.12 
49 73 0.94 0.32 2.56 0.55 1.64 1.05 0.36   0.94 0.19 2.56 0.44 1.51 1.00 0.15 
50 74 0.01 0.01 0.00 0.00 0.74 0.32 0.04   0.01 0.00 0.00 0.00 0.72 0.32 0.00 
51 75 0.39 0.27 0.53 0.20 0.44 0.90 0.64   0.39 0.22 0.53 0.11 0.38 0.88 0.54 
52 76 0.20 0.46 0.51 0.31 7.38 2.13 33.76   0.20 0.43 0.51 0.08 5.98 2.12 33.00 
53 77 17.82 49.21 32.79 5.63 9.56 4.40 3.16   17.82 46.89 32.79 5.25 9.34 3.51 2.12 
54 78 19.77 23.20 66.63 3.60 23.11 8.83 8.01   19.77 20.64 66.63 2.73 22.58 7.84 5.54 
55 79 0.01 0.05 0.00 0.01 11.32 2.68 1.24   0.01 0.04 0.00 0.00 11.21 2.68 0.12 
56 80 23.24 16.58 1.58 1.62 1.23 2.95 1.35   23.24 13.56 1.58 1.42 1.11 1.78 1.11 
57 82 2.72 1.25 2.75 1.57 23.60 8.04 448.04   2.72 0.90 2.75 0.70 5.47 7.90 445.52 
58 83 2.99 6.19 1.03 0.55 475.86 74.50 2.99   2.99 5.80 1.03 0.00 472.89 74.35 0.00 
59 84 12.34 10.75 1.42 0.49 0.34 1.44 0.20   12.34 9.15 1.42 0.40 0.31 0.83 0.12 
60 85 1.93 25.53 0.63 0.76 1.53 3.16 0.21   1.93 25.28 0.63 0.43 1.41 3.07 0.00 
61 86 0.04 0.05 0.00 0.00 0.00 0.00 0.00   0.04 0.04 0.00 0.00 0.00 0.00 0.00 
62 87 0.10 0.51 0.03 0.04 37.07 12.55 1.39   0.10 0.50 0.03 0.00 36.57 12.54 0.00 
63 90 2.44 0.32 13.47 0.15 2.77 11.88 0.42   2.44 0.00 13.47 0.00 2.30 11.76 0.00 
64 91 13.18 25.64 0.24 0.27 0.22 2.49 0.19   13.18 23.93 0.24 0.07 0.14 1.83 0.03 
65 94 0.01 0.07 0.02 0.01 0.01 0.00 0.00   0.01 0.07 0.02 0.01 0.00 0.00 0.00 
66 95 0.10 0.13 0.01 0.00 0.00 0.00 0.00   0.10 0.12 0.01 0.00 0.00 0.00 0.00 
67 96 0.03 0.02 0.02 0.00 0.00 0.00 0.00   0.03 0.01 0.02 0.00 0.00 0.00 0.00 
68 97 0.01 0.01 0.00 0.00 0.00 0.00 0.00   0.01 0.01 0.00 0.00 0.00 0.00 0.00 
69 99 0.02 0.16 0.08 0.00 0.01 0.00 0.00   0.02 0.15 0.08 0.00 0.01 0.00 0.00 
70 100 0.06 0.35 0.02 0.00 0.07 0.02 0.02   0.06 0.34 0.02 0.00 0.07 0.02 0.01 
71 101 0.00 0.00 0.00 0.00 0.03 0.01 0.44   0.00 0.00 0.01 0.00 0.01 0.00 0.43 
72 102 0.02 0.22 0.01 0.00 0.00 0.01 0.00   0.02 0.22 0.01 0.00 0.00 0.01 0.00 
73 103 0.01 0.02 0.01 0.00 0.00 0.00 0.00   0.01 0.02 0.01 0.00 0.00 0.00 0.00 
74 104 0.00 0.00 0.01 0.04 0.00 0.00 0.01   0.00 0.00 0.01 0.04 0.00 0.00 0.01 
75 106 0.09 0.02 0.00 0.00 0.00 0.00 0.00   0.09 0.01 0.00 0.00 0.00 0.00 0.00 
76 108 0.02 0.10 0.01 0.00 0.00 0.01 0.01   0.02 0.10 0.01 0.00 0.00 0.01 0.00 
77 109 0.08 0.13 0.01 0.00 0.00 0.01 0.00   0.08 0.12 0.01 0.00 0.00 0.00 0.00 
78 110 0.10 0.14 0.07 0.01 0.02 0.01 0.00   0.10 0.13 0.07 0.01 0.02 0.00 0.00 
79 111 0.00 0.00 0.00 0.00 0.13 0.05 0.01   0.00 0.00 0.00 0.00 0.13 0.05 0.00 
80 112 0.11 0.02 0.00 0.00 0.00 0.00 0.00   0.11 0.00 0.00 0.00 0.00 0.00 0.00 
81 113 0.00 0.00 0.03 0.00 0.00 0.01 0.00   0.00 0.00 0.00 0.03 0.00 0.00 0.01 
82 115 0.00 0.01 0.02 0.67 0.04 0.05 0.11   0.00 0.00 0.02 0.66 0.03 0.05 0.10 
83 117 0.00 0.00 0.01 0.00 0.00 0.00 0.00   0.00 0.00 0.01 0.00 0.00 0.00 0.00 
84 118 0.02 0.01 0.00 0.00 0.00 0.00 0.00   0.02 0.00 0.00 0.00 0.00 0.00 0.00 
85 119 0.00 0.01 0.43 0.01 0.06 0.02 0.03   0.00 0.01 0.43 0.00 0.05 0.01 0.03 
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Appendix B.Comparison data on 85 patients between CSCT results and IRS results, 
both expressed in percentages. 
    CSCT (corrected)       IRS    
  COD COM CP CPD UA MAP CYS  COD COM CP CPD UA MAP CYS 
1 4 5 1 14 0 4 50 26   40 60 0 0 0 0 0 
2 15 0 0 0 0 87 13 0   0 20 0 0 80 0 0 
3 17 2 3 9 0 12 7 67   0 0 0 0 0 20 80 
4 21 12 78 3 1 2 3 1   10 90 0 0 0 0 0 
5 23 12 74 7 2 2 2 1   10 90 0 0 0 0 0 
6 24 1 2 0 0 85 7 5   0 0 0 0 80 20 0 
7 25 2 2 84 1 8 2 1   0 0 100 0 0 0 0 
8 26 25 50 16 6 2 0 1   30 70 0 0 0 0 0 
9 27 37 48 6 2 3 3 1   20 80 0 0 0 0 0 
10 28 2 3 75 3 12 3 2   0 0 100 0 0 0 0 
11 29 1 1 21 68 4 1 4   0 0 0 100 0 0 0 
12 32 0 9 0 0 81 5 5   0 0 0 0 80 20 0 
13 33 4 83 5 1 3 3 1   10 90 0 0 0 0 0 
14 34 25 24 38 4 2 6 1   65 0 35 0 0 0 0 
15 35 38 27 21 3 1 9 1   0 95 5 0 0 0 0 
16 36 1 2 6 0 6 3 82   0 0 0 0 0 0 100 
17 37 15 66 9 3 1 4 2   20 80 0 0 0 0 0 
18 38 2 5 8 1 4 7 73   0 0 0 0 0 0 100 
19 39 4 61 7 8 7 8 5   40 60 0 0 0 0 0 
20 41 32 7 16 26 0 5 14   0 0 10 0 0 90 0 
21 42 27 7 1 14 32 1 18   0 0 0 0 100 0 0 
22 43 45 22 7 22 0 0 4   20 80 0 0 0 0 0 
23 45 27 11 1 18 24 0 19   10 90 0 0 0 0 0 
24 46 48 3 6 17 3 16 7   65 0 35 0 0 0 0 
25 47 27 20 24 13 8 4 4   65 0 35 0 0 0 0 
26 48 8 1 2 10 7 8 64   0 0 0 0 0 0 100 
27 49 28 55 2 4 5 5 1   10 80 0 0 0 10 0 
28 50 47 17 19 10 5 0 2   95 5 0 0 0 0 0 
29 51 1 1 4 0 12 3 79   0 0 0 0 0 0 100 
30 52 5 0 3 84 1 5 2   0 0 0 100 0 0 0 
31 53 0 0 1 0 1 8 90   0 0 0 20 0 0 80 
32 54 16 69 0 4 5 4 2   10 90 0 0 0 0 0 
33 55 1 1 7 85 0 1 5   0 0 0 100 0 0 0 
34 57 4 39 23 6 19 5 4   10 80 10 0 0 0 0 
35 58 0 1 0 0 2 7 90   0 0 0 0 0 0 100 
36 60 14 68 1 5 4 6 2   10 90 0 0 0 0 0 
37 61 49 19 10 6 4 7 5   65 0 35 0 0 0 0 
38 62 56 19 9 7 5 2 2   95 5 0 0 0 0 0 
39 63 23 29 0 2 40 6 0   0 50 0 0 50 0 0 
40 64 10 64 11 3 7 4 1   0 95 5 0 0 0 0 
41 65 3 47 0 0 37 13 0   0 60 0 0 40 0 0 
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42 66 16 75 1 2 3 2 1   10 90 0 0 0 0 0 
43 67 12 5 43 6 20 11 3   0 0 100 0 0 0 0 
44 68 18 70 1 2 3 4 2   10 90 0 0 0 0 0 
45 69 0 1 0 0 74 25 0   0 0 0 0 100 0 0 
46 70 25 49 3 4 9 7 3   95 5 0 0 0 0 0 
47 71 1 4 0 0 69 26 0   0 0 0 0 100 0 0 
48 72 2 0 0 0 62 35 1   0 0 0 0 100 0 0 
49 73 14 3 37 6 23 15 2   0 0 100 0 0 0 0 
50 74 1 0 0 0 68 31 0   0 0 0 0 100 0 0 
51 75 13 7 17 3 13 29 18   0 0 10 0 0 90 0 
52 76 1 1 1 0 14 5 78   0 0 0 0 0 0 100 
53 77 15 40 28 4 8 3 2   10 90 0 0 0 0 0 
54 78 14 14 46 2 15 5 4   0 0 100 0 0 0 0 
55 79 0 0 0 0 80 19 1   0 0 0 0 100 0 0 
56 80 53 31 3 3 3 4 3   10 90 0 0 0 0 0 
57 82 1 0 1 0 1 1 96   0 0 0 0 0 0 100 
58 83 0 1 0 0 85 14 0   0 0 0 0 80 20 0 
59 84 50 38 6 2 1 3 0   20 80 0 0 0 0 0 
60 85 6 78 2 1 4 9 0   0 95 5 0 0 0 0 
61 86 40 50 3 5 1 0 1   40 60 0 0 0 0 0 
62 87 0 1 0 0 74 25 0   0 0 0 0 100 0 0 
63 90 8 0 45 0 8 39 0   0 0 20 0 0 80 0 
64 91 33 61 1 0 0 5 0   10 90 0 0 0 0 0 
65 94 12 58 20 5 4 1 0   10 90 0 0 0 0 0 
66 95 41 50 6 1 1 0 1   20 80 0 0 0 0 0 
67 96 45 16 31 3 1 1 3   30 60 10 0 0 0 0 
68 97 40 31 10 10 6 0 3   65 0 35 0 0 0 0 
69 99 9 58 30 0 2 1 0   15 70 15 0 0 0 0 
70 100 12 66 3 0 14 3 2   0 80 0 0 20 0 0 
71 101 0 0 0 0 2 0 98   0 0 0 0 0 0 100 
72 102 7 81 5 1 1 5 0   0 100 0 0 0 0 0 
73 103 15 45 30 3 3 2 2   0 80 10 0 0 10 0 
74 104 3 1 20 57 5 6 8   0 0 0 80 0 20 0 
75 106 87 8 2 1 1 0 0   30 60 10 0 0 0 0 
76 108 17 68 7 0 1 4 3   10 90 0 0 0 0 0 
77 109 38 56 3 1 1 0 1   20 80 0 0 0 0 0 
78 110 31 41 21 2 5 0 0   40 60 0 0 0 0 0 
79 111 0 2 0 0 70 28 0   0 0 0 0 100 0 0 
80 112 93 4 0 2 1 0 0   80 20 0 0 0 0 0 
81 113 0 0 72 0 0 22 6   0 0 30 0 0 70 0 
82 115 0 1 2 76 3 6 12   0 0 0 100 0 0 0 
83 117 16 22 55 0 0 7 0   0 80 20 0 0 0 0 
84 118 70 14 3 3 0 7 3   40 60 0 0 0 0 0 
85 119 0 2 79 1 10 3 5   0 0 100 0 0 0 0 
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